PL417879A1 - Zastosowanie pochodnej kwasu 7-aminocefalosporanowego jako inhibitora aktywności biologicznej IL-15 i IL-2 - Google Patents

Zastosowanie pochodnej kwasu 7-aminocefalosporanowego jako inhibitora aktywności biologicznej IL-15 i IL-2

Info

Publication number
PL417879A1
PL417879A1 PL417879A PL41787914A PL417879A1 PL 417879 A1 PL417879 A1 PL 417879A1 PL 417879 A PL417879 A PL 417879A PL 41787914 A PL41787914 A PL 41787914A PL 417879 A1 PL417879 A1 PL 417879A1
Authority
PL
Poland
Prior art keywords
derivative
aminocephalosporanic acid
applications
biologic activity
activity inhibitor
Prior art date
Application number
PL417879A
Other languages
English (en)
Other versions
PL235635B1 (pl
Inventor
Katarzyna Koziak
Barbara Żyżyńska-Granica
Sławomir Filipek
Szymon Niewieczerzał
Bartosz Trzaskowski
Oliwia Zegrocka-Stendel
Małgorzata Dutkiewicz
Piotr Krzeczyński
Elżbieta Kaczmarek
Magdalena Winiarska
Original Assignee
Warszawski Uniwersytet Medyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warszawski Uniwersytet Medyczny filed Critical Warszawski Uniwersytet Medyczny
Publication of PL417879A1 publication Critical patent/PL417879A1/pl
Publication of PL235635B1 publication Critical patent/PL235635B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Ujawniono zastosowanie pochodnej kwasu 7-aminocefalosporanowego - cefazoliny w leczeniu i zapobieganiu chorób, u podłoża których leży nadmierna produkcja interleukiny 15 i interleukiny 2. Przedmiotem zgłoszenia jest także preparat farmaceutyczny zawierający terapeutycznie skuteczną ilość cefazoliny jako substancję aktywną oraz farmaceutycznie dopuszczalne nośniki i/lub substancje pomocnicze, do stosowania w zapobieganiu lub leczeniu chorób takich jak łuszczyca, zapalenie jelit, sarkoidoza, białaczki T-komórkowe lub odrzucanie przeszczepów. Ponadto, preparat farmaceutyczny ma postać odpowiednią do podawania dożylnie lub domięśniowo.
PL417879A 2013-09-30 2014-09-29 Pochodna kwasu 7-aminocefalosporanowego-cefazolina oraz zawierający ją preparat farmaceutyczny do zastosowania w leczeniu i zapobieganiu chorób, u podłoża których leży nadmierna produkcja interleukiny 15 oraz interleukiny 2 PL235635B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL40550613A PL405506A1 (pl) 2013-09-30 2013-09-30 Zastosowanie pochodnej kwasu 7-aminocefalosporanowego jako inhibitora aktywności biologicznej IL-15 i IL-2
PCT/IB2014/001940 WO2015044762A1 (en) 2013-09-30 2014-09-29 7-aminocephalosporanic acid derivative as inhibitor of il-15 and il-2 activity

Publications (2)

Publication Number Publication Date
PL417879A1 true PL417879A1 (pl) 2017-02-13
PL235635B1 PL235635B1 (pl) 2020-09-21

Family

ID=51903949

Family Applications (3)

Application Number Title Priority Date Filing Date
PL40550613A PL405506A1 (pl) 2013-09-30 2013-09-30 Zastosowanie pochodnej kwasu 7-aminocefalosporanowego jako inhibitora aktywności biologicznej IL-15 i IL-2
PL417879A PL235635B1 (pl) 2013-09-30 2014-09-29 Pochodna kwasu 7-aminocefalosporanowego-cefazolina oraz zawierający ją preparat farmaceutyczny do zastosowania w leczeniu i zapobieganiu chorób, u podłoża których leży nadmierna produkcja interleukiny 15 oraz interleukiny 2
PL14799527T PL3068491T3 (pl) 2013-09-30 2014-09-29 Pochodna kwasu 7-aminocefalosporanowego jako inhibitor aktywności IL-15 oraz IL-2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL40550613A PL405506A1 (pl) 2013-09-30 2013-09-30 Zastosowanie pochodnej kwasu 7-aminocefalosporanowego jako inhibitora aktywności biologicznej IL-15 i IL-2

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL14799527T PL3068491T3 (pl) 2013-09-30 2014-09-29 Pochodna kwasu 7-aminocefalosporanowego jako inhibitor aktywności IL-15 oraz IL-2

Country Status (9)

Country Link
US (2) US20160235762A1 (pl)
EP (1) EP3068491B1 (pl)
AU (2) AU2014326355B2 (pl)
CA (1) CA2925652A1 (pl)
DK (1) DK3068491T3 (pl)
ES (1) ES2747635T3 (pl)
PL (3) PL405506A1 (pl)
PT (1) PT3068491T (pl)
WO (1) WO2015044762A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3124016T (pt) 2015-07-31 2019-12-13 Univ Warszawski Medyczny Composição de emulsão antipsoriática que compreende cefazolina
CA3061328A1 (en) 2017-04-24 2018-11-01 University Of Massachusetts Diagnosis and treatment of vitiligo
WO2024137136A1 (en) * 2022-12-22 2024-06-27 University Of Houston System Inhibitors of il-15 and their use in treating or preventing sepsis, severe sepsis and septic shock

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891370A (en) 1981-12-14 1990-01-02 Merck & Co., Inc. Cephalosporin derivatives as anti-inflammatory agents
CN1247057A (zh) * 1999-06-07 2000-03-15 李桂华 口腔保洁剂的配制方法
EP1531828A4 (en) * 2002-05-23 2005-11-02 Activbiotics Inc METHODS OF TREATING BACTERIAL INFECTIONS AND ASSOCIATED DISEASES
JP2007131535A (ja) * 2003-12-26 2007-05-31 Tokai Univ 蛋白修飾物生成抑制剤
CU23472A1 (es) 2004-09-17 2009-12-17 Ct Ingenieria Genetica Biotech Péptido antagonista de la interleucina-15
US20070202077A1 (en) 2005-12-02 2007-08-30 Brodsky Robert A Use of High-Dose Oxazaphosphorine Drugs for Treating Immune Disorders
CU23716A1 (es) 2008-09-30 2011-10-05 Ct Ingenieria Genetica Biotech Péptido antagonista de la actividad de la interleucina-15

Also Published As

Publication number Publication date
US20160235762A1 (en) 2016-08-18
ES2747635T3 (es) 2020-03-11
EP3068491B1 (en) 2019-07-03
AU2019236714B2 (en) 2020-10-15
WO2015044762A1 (en) 2015-04-02
AU2014326355B2 (en) 2019-06-27
AU2019236714A1 (en) 2019-10-17
PL405506A1 (pl) 2015-04-13
PL235635B1 (pl) 2020-09-21
PL3068491T3 (pl) 2019-12-31
DK3068491T3 (da) 2019-10-14
PT3068491T (pt) 2019-10-24
US11452728B2 (en) 2022-09-27
AU2014326355A1 (en) 2016-04-28
CA2925652A1 (en) 2015-04-02
US20170319593A1 (en) 2017-11-09
EP3068491A1 (en) 2016-09-21

Similar Documents

Publication Publication Date Title
ZA202308495B (en) Pharmaceutical compositions of therapeutically active compounds
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
PH12016501355B1 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
MX392606B (es) Composiciones para la liberacion controlada de cisteamina y el tratamiento sistemico de trastornos sensibles a la cisteamina.
MX2016009666A (es) Suministro topico de composiciones para la piel que tienen ph bajo.
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
PH12016501788A1 (en) Pharmaceutical compositions of therapeutically active compounds
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
PH12015502365A1 (en) Bace1 inhibitors
EP4360621A3 (en) Formulations of bendamustine
JOP20200004A1 (ar) تركيبات طويلة المفعول
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
MX2016000964A (es) Composiciones farmaceuticas para la administracion intraocular que comprenden un agente antibacteriano y un agente antiinflamatorio.
MY193740A (en) "substituted 2,4 diamino-quinoline as new anticancer agents"
GEAP202215599A (en) Boron containing pde4 inhibitors
MX377032B (es) Compuestos de dihidroquinolinsulfonamida de alquilo.
PL417879A1 (pl) Zastosowanie pochodnej kwasu 7-aminocefalosporanowego jako inhibitora aktywności biologicznej IL-15 i IL-2
PH12017501668A1 (en) Bace1 inhibitors
PL417876A1 (pl) Zastosowania pochodnej kwasu diaminodikarboksylowego jako inhibitora aktywności biologicznej IL-15 i IL-2
MY199579A (en) New use of isoquinoline derivatives for diabetic wound healing
CO2018005367A2 (es) Composición farmacéutica que contiene, como ingrediente activo, derivado de 7-azaindolin-2-ona o sal farmacéuticamente aceptable del mismo campo técnico
ZA201606135B (en) Pharmaceutical compositions of therapeutically active compounds
CL2016000222A1 (es) Composiciones tópicas para el tratamiento de sudoración excesiva y métodos para utilizar las mismas
UA106471U (uk) Засіб для лікування дерматологічних захворювань
HK1233185A1 (en) Pharmaceutical compositions of therapeutically active compounds